APA (7th ed.) Citation

von Pawel, J., Spigel, D. R., Ervin, T., Losonczy, G., Barlesi, F., Juhász, E., . . . Reck, M. (2018). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer. The oncologist (Dayton, Ohio), 23(6), 654-e58. https://doi.org/10.1634/theoncologist.2017-0690

Chicago Style (17th ed.) Citation

von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio) 23, no. 6 (2018): 654-e58. https://doi.org/10.1634/theoncologist.2017-0690.

MLA (9th ed.) Citation

von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio), vol. 23, no. 6, 2018, pp. 654-e58, https://doi.org/10.1634/theoncologist.2017-0690.